Abstract
Background: Oxaliplatin (OXA) is a third-generation platinum based chemotherapy used in the treatment of colorectal cancer (CRC). We recently showed by gene set enrichment analysis (GSEA) that subactive doses of OXA induce adaptive changes in CRC cell lines, with preservation of cell viability (Tosi et al, ASCO Annual Meeting 2022, abstr. #3091). In particular, a widespread negative enrichment of gene sets involved in DNA repair was detected both at 24 and at 48 hours, with a far greater negative enrichment at 48 hours, which suggest a commitment of cancer cell to a major limitation of DNA repairing capability following a DNA damaging insult.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
